Latest Diagnostics News

Page 36 of 59
BCAL Diagnostics has partnered with Sonic Healthcare Australia to broaden access to its innovative blood-based breast cancer test, BREASTEST plus™, across Sydney. This move formalizes a commercial rollout following successful trials and aims to improve early detection for women with dense breast tissue.
Ada Torres
Ada Torres
27 Aug 2025
Proteomics International Laboratories reported a 26% increase in losses for FY2025, driven by higher operational costs as it advances its Promarker® diagnostic pipeline. Despite an 8% rise in revenue from ordinary activities, total income slipped 2%, underscoring ongoing commercialisation challenges.
Ada Torres
Ada Torres
27 Aug 2025
Mach7 Technologies reported a robust FY25 with 16% revenue growth and a strategic pivot towards customer-centric innovation, underpinned by leadership changes and a strong financial position.
Victor Sage
Victor Sage
27 Aug 2025
AnteoTech Ltd reported a 110% revenue increase to A$968,878 in FY2025 alongside a 24% reduction in net loss, driven by strategic cost savings and key partnerships. Leadership renewal and product validation position the company for growth in battery and life sciences markets.
Victor Sage
Victor Sage
27 Aug 2025
Mach7 Technologies Limited reported a 16% revenue increase to AUD 33.8 million for FY25, alongside a 22% reduction in net loss, driven by a strategic shift to subscription-based sales and disciplined cost management.
Victor Sage
Victor Sage
27 Aug 2025
Apiam Animal Health posted modest FY25 growth amid challenges in clinical services, launching a Strategic Reset Program and attracting an acquisition proposal from Adamantem Capital.
Ada Torres
Ada Torres
27 Aug 2025
Apiam Animal Health reported modest revenue growth but a sharp net profit decline in FY25, launching a Strategic Reset program under new leadership. The company also received a $0.88 per share acquisition proposal from Adamantem Capital Management.
Ada Torres
Ada Torres
27 Aug 2025
Cleo Diagnostics reported a $4 million loss for FY2025 while making significant strides toward FDA approval of its novel ovarian cancer blood test. The company is progressing clinical trials and scaling manufacturing in preparation for market entry.
Ada Torres
Ada Torres
26 Aug 2025
Microba Life Sciences reported a 30% increase in revenue to $15.7 million for FY25, driven by strong growth in its core microbiome diagnostic products and successful UK market expansion. Despite narrowing its net loss to $14.9 million, the company is focused on scaling diagnostics adoption and achieving break-even in FY26.
Ada Torres
Ada Torres
26 Aug 2025
Integral Diagnostics (IDX) reported a robust FY25 with 33.7% revenue growth and operating EBITDA margin expansion, driven by the Capitol merger and organic growth. The company exceeded synergy expectations and outlined a confident outlook amid favourable industry tailwinds.
Ada Torres
Ada Torres
26 Aug 2025
BlinkLab Limited has expanded its pivotal FDA autism diagnostic trial by partnering with two leading US pediatric institutions, enhancing recruitment and clinical credibility ahead of its 2026 submission.
Ada Torres
Ada Torres
26 Aug 2025
Integral Diagnostics posts robust FY25 results with strong revenue growth and merger synergies exceeding expectations, setting a confident tone for FY26.
Ada Torres
Ada Torres
26 Aug 2025